AHR and cancer: Several strategies have been outlined by Peyraud et al. including three different strategies that target the IDO/TDO-Kyn-AhR signaling circuit in cancer treatment: (i) pharmacological inhibition of IDO/TDO by IDO inhibitors, (ii), systemic depletion of Kyn by engineered kynureninase, and (iii) blockade of AhR activation by synthetic AhR modulators [82] (Table 2).